State Farm Mutual Automobile Insurance’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-446,061
| Closed | -$9.51M | – | 125 |
|
|
2024
Q1 | $9.51M | Hold |
446,061
| – | – | 0.01% | 106 |
|
|
2023
Q4 | $8.54M | Hold |
446,061
| – | – | 0.01% | 106 |
|
|
2023
Q3 | $7.15M | Hold |
446,061
| – | – | 0.01% | 107 |
|
|
2023
Q2 | $10.3M | Hold |
446,061
| – | – | 0.01% | 106 |
|
|
2023
Q1 | $10.4M | Hold |
446,061
| – | – | 0.01% | 108 |
|
|
2022
Q4 | $6.47M | Hold |
446,061
| – | – | 0.01% | 108 |
|
|
2022
Q3 | $8.51M | Hold |
446,061
| – | – | 0.01% | 103 |
|
|
2022
Q2 | $8.11M | Hold |
446,061
| – | – | 0.01% | 106 |
|
|
2022
Q1 | $11.2M | Hold |
446,061
| – | – | 0.01% | 106 |
|
|
2021
Q4 | $12.3M | Hold |
446,061
| – | – | 0.01% | 104 |
|
|
2021
Q3 | $14.4M | Hold |
446,061
| – | – | 0.02% | 103 |
|
|
2021
Q2 | $13.6M | Hold |
446,061
| – | – | 0.01% | 102 |
|
|
2021
Q1 | $13.6M | Hold |
446,061
| – | – | 0.01% | 97 |
|
|
2020
Q4 | $8.82M | Hold |
446,061
| – | – | 0.01% | 102 |
|
|
2020
Q3 | $5.82M | Hold |
446,061
| – | – | 0.01% | 102 |
|
|
2020
Q2 | $5.06M | Hold |
446,061
| – | – | 0.01% | 103 |
|
|
2020
Q1 | $6.38M | Hold |
446,061
| – | – | 0.01% | 96 |
|
|
2019
Q4 | $12.1M | Hold |
446,061
| – | – | 0.02% | 91 |
|
|
2019
Q3 | $12.8M | Hold |
446,061
| – | – | 0.02% | 93 |
|
|
2019
Q2 | $12.4M | Buy |
446,061
+41,333
| +10% | +$1.17M | 0.02% | 92 |
|
|
2019
Q1 | $13.4M | Hold |
404,728
| – | – | 0.02% | 89 |
|
|
2018
Q4 | $11.8M | Hold |
404,728
| – | – | 0.02% | 87 |
|
|
2018
Q3 | $18.6M | Hold |
404,728
| – | – | 0.02% | 85 |
|
|
2018
Q2 | $15.1M | Hold |
404,728
| – | – | 0.02% | 87 |
|
|
2018
Q1 | $12M | Hold |
404,728
| – | – | 0.02% | 88 |
|
|
2017
Q4 | $13.9M | Hold |
404,728
| – | – | 0.02% | 87 |
|
|
2017
Q3 | $14.6M | Hold |
404,728
| – | – | 0.02% | 88 |
|
|
2017
Q2 | $10.5M | Hold |
404,728
| – | – | 0.01% | 91 |
|
|
2017
Q1 | $7.77M | Hold |
404,728
| – | – | 0.01% | 93 |
|
|
2016
Q4 | $6.75M | Buy |
404,728
+226,353
| +127% | +$4.1M | 0.01% | 94 |
|
|
2016
Q3 | $3.67M | Hold |
178,375
| – | – | 0.01% | 100 |
|
|
2016
Q2 | $5.46M | Hold |
178,375
| – | – | 0.01% | 97 |
|
|
2016
Q1 | $6.68M | Hold |
178,375
| – | – | 0.01% | 95 |
|
|
2015
Q4 | $7.7M | Hold |
178,375
| – | – | 0.01% | 90 |
|
|
2015
Q3 | $6.68M | Hold |
178,375
| – | – | 0.01% | 90 |
|
|
2015
Q2 | $6.06M | Hold |
178,375
| – | – | 0.01% | 97 |
|
|
2015
Q1 | $6.31M | Hold |
178,375
| – | – | 0.01% | 96 |
|
|
2014
Q4 | $6.08M | Hold |
178,375
| – | – | 0.01% | 97 |
|
|
2014
Q3 | $6.88M | Hold |
178,375
| – | – | 0.01% | 93 |
|
|
2014
Q2 | $6.94M | Buy |
178,375
+26,575
| +18% | +$989K | 0.01% | 93 |
|
|
2014
Q1 | $5.19M | Hold |
151,800
| – | – | 0.01% | 101 |
|
|
2013
Q4 | $3.19M | Hold |
151,800
| – | – | 0.01% | 106 |
|
|
2013
Q3 | $3.57M | Buy |
+151,800
| New | +$4.31M | 0.01% | 104 |
|
Other funds holding MYGN
CCM
GCM
State Farm Mutual Automobile Insurance's MYGN Position: Q2 2024 in Review
State Farm Mutual Automobile Insurance sold out of Myriad Genetics (MYGN) in Q2 2024, closing a stake of 446,061 shares — an estimated $9.51M sold.
State Farm Mutual Automobile Insurance first reported a position in MYGN in Q3 2013 and held it in 43 quarters. The position peaked at $18.6M in Q3 2018. 223 funds tracked by Wall St. Rank hold MYGN as of Q2 2024.
- State Farm Mutual Automobile Insurance reported no remaining Myriad Genetics position as of Q2 2024 after selling out during the quarter.
- State Farm Mutual Automobile Insurance sold 446,061 Myriad Genetics shares in Q2 2024, an estimated $9.51M.
- State Farm Mutual Automobile Insurance first reported a position in Myriad Genetics in Q3 2013 and held it in 43 quarters.
- State Farm Mutual Automobile Insurance's Myriad Genetics position peaked at $18.6M in Q3 2018.
- 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2024.
Based on State Farm Mutual Automobile Insurance's 13F filing for Q2 2024, filed 12 Aug 2024.